Literature DB >> 23282306

Colon carcinogenesis in inflammatory bowel disease.

S H Itzkowitz1, B Greenwald, S J Meltzer.   

Abstract

: Colon cancers arising in the setting of chronic inflammatory bowel disease (IBD) share only some of the clinicopathological features with sporadic colon cancers. Whereas much is known about the molecular alterations involved in sporadic colon cancer, less is known in this regard with respect to colitis-associated neoplasms. Of the phenotypic alterations that have been most widely studied, increases in sialomucin and decreases in sialic acid O-acetylation appear to correlate with malignant progression in IBD. These mucin alterations, exemplified by sialosyl-Tn antigen, suggest that small intestinal metaplasia occurs as part of the carcinogenic process. At the molecular genetic level, genomic instability and clonal evolution, as evidenced by abnormal DNA content (aneuploidy) are associated with malignant progression. The activation of specific protooncogenes (k-ras, c-src) and the loss or mutation of certain tumor suppressor genes (p53, APC) occur in colitis-associated colon neoplasms, although the frequency and chronology of these alterations may differ from that of sporadic carcinogenesis. Microsatellite instability also occurs during colitisassociated carcinogenesis, but mutations in DNA mismatch repair genes often associated with this molecular alteration have not yet been described. Additional research will be required to elucidate the basic pathobiology of carcinogenesis in IBD and to determine how this knowledge can be used to influence clinical management of patients.

Entities:  

Year:  1995        PMID: 23282306

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  7 in total

1.  Expression of apoptosis related proteins during malignant progression in chronic ulcerative colitis.

Authors:  C J van der Woude; H Moshage; M Homan; J H Kleibeuker; P L M Jansen; H van Dekken
Journal:  J Clin Pathol       Date:  2005-08       Impact factor: 3.411

Review 2.  Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis.

Authors:  Marco Scarpa; Ignazio Castagliuolo; Carlo Castoro; Anna Pozza; Melania Scarpa; Andromachi Kotsafti; Imerio Angriman
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 3.  Microscopic features of colorectal neoplasia in inflammatory bowel diseases.

Authors:  Aude Bressenot; Virginie Cahn; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

4.  Layered signaling regulatory networks analysis of gene expression involved in malignant tumorigenesis of non-resolving ulcerative colitis via integration of cross-study microarray profiles.

Authors:  Shengjun Fan; Zhenyu Pan; Qiang Geng; Xin Li; Yefan Wang; Yu An; Yan Xu; Lu Tie; Yan Pan; Xuejun Li
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

Review 5.  Chinese herbal medicines in the treatment of IBD and colorectal cancer: a review.

Authors:  Maciej Sałaga; Hubert Zatorski; Marta Sobczak; Chunqiu Chen; Jakub Fichna
Journal:  Curr Treat Options Oncol       Date:  2014-09

Review 6.  p53 Expression as a Diagnostic Biomarker in Ulcerative Colitis-Associated Cancer.

Authors:  Kazuhiro Kobayashi; Hiroyuki Tomita; Masahito Shimizu; Takuji Tanaka; Natsuko Suzui; Tatsuhiko Miyazaki; Akira Hara
Journal:  Int J Mol Sci       Date:  2017-06-16       Impact factor: 5.923

7.  ST6GALNAC1 plays important roles in enhancing cancer stem phenotypes of colorectal cancer via the Akt pathway.

Authors:  Tadashi Ogawa; Yoshihiko Hirohashi; Aiko Murai; Toshihiko Nishidate; Kenji Okita; Liming Wang; Yuzuru Ikehara; Tetsuta Satoyoshi; Akihiro Usui; Terufumi Kubo; Munehide Nakastugawa; Takayuki Kanaseki; Tomohide Tsukahara; Goro Kutomi; Tomohisa Furuhata; Koichi Hirata; Noriyuki Sato; Toru Mizuguchi; Ichiro Takemasa; Toshihiko Torigoe
Journal:  Oncotarget       Date:  2017-11-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.